Latest news with #NovartisAG
Bloomberg
6 days ago
- Business
- Bloomberg
Stock Movers: ABB, Legrand, Novartis
On this episode of Stock Movers: - ABB Ltd. rallied after the company reported record order intake and profit margins that surpassed views, spurred by rising demand for automation tools and data center-driven investments in electrical grids. Orders surged 16% in the second quarter to $9.79 billion, lifted by a single $600 million deal for process-automation tools in the US, the Zurich-based industrial supplier said Thursday in a statement. ABB shares gained as much as 8.5%, the most intraday in over three months. - Legrand shares are trading at a record high this morning after jumping as much as 8.4% as the electrical device specialist posted organic growth well ahead of expectations in the second quarter and raised its outlook for the full year. Analysts cited strong demand for data centers in North America. - Novartis AG slumped after disappointing sales for its key psoriasis drug and the looming retirement of its respected finance chief overshadowed a modest outlook raise. Core operating profit will likely grow by a percentage in the low teens, the Swiss drugmaker said Thursday. New medicines made up for lackluster growth from the psoriasis treatment Cosentyx, which analysts pointed to as a concern. The shares fell as much as 2.8% in early Zurich trading, trimming this year's gain to about 5%.
Business Insider
7 days ago
- Business
- Business Insider
Kepler Capital Sticks to Their Buy Rating for Novartis AG (NOVN)
Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on July 14 and set a price target of CHF106.00. The company's shares closed yesterday at CHF96.06. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Evans is a 2-star analyst with an average return of 0.1% and a 55.72% success rate. Evans covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novartis AG, and Novo Nordisk. Novartis AG has an analyst consensus of Moderate Buy, with a price target consensus of CHF102.20, a 6.39% upside from current levels. In a report released on July 4, Deutsche Bank also maintained a Buy rating on the stock with a CHF115.00 price target. Based on Novartis AG's latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of CHF13.62 billion and a net profit of CHF3.61 billion. In comparison, last year the company earned a revenue of CHF12.12 billion and had a net profit of CHF2.69 billion
Globe and Mail
14-07-2025
- Business
- Globe and Mail
Precision Diagnostics & Medicine Market worth $246.66 billion by 2029
"Key players in the Precision diagnostic market include F. Hoffman La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), and Guardant Health (US) among others and key players in precision medicine market include Merck Co, Inc. (US), Gilead Sciences (US), AstraZeneca (UK), Novartis AG (Switzerland), among others." Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029 The report " Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029", is expected to reach USD 246.66 billion by 2029 from USD 145.53 billion in 2024, growing at a CAGR of 11.1% Factors such as the increasing integration of AI and ML for the development of advanced precision diagnostics and therapeutic solutions supported by the rising collaboration and investment by major pharmaceutical companies for the development of precision medicine and biomarker discovery drive the growth of the market. Moreover, the increasing demand for direct-to-consumer testing owing to the growing awareness of patients towards their health and the convenience offered by these tests supports the adoption of precision diagnostics. Additionally, the expanding focus of pharmaceutical companies on the development of precision solutions for other diseases such as neurodegenerative disorders and autoimmune diseases and the integration of wearable technology to enhance healthcare offers growth opportunities for players operating in the precision medicine market. However, factors such as the high cost of precision healthcare and the challenges related to the integration and management of big data in precision solution development restrain the growth of the market. Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication (Oncology, Neurology, Immunology), Therapeutic Products (Inhibitors, mAbs, CGT), Indication (Oncology, Rare Disease, Infectious) - Global Forecast to 2029"View detailed Table of Content here - The monoclonal antibodies segment accounted for the largest share of the Precision Medicine Market, by product, during the forecast period. Based on products, the precision medicine market is divided into inhibitor drugs, monoclonal antibodies, cell and gene therapy, antiviral and anti-retroviral drugs, and other therapeutic products. The large share of the monoclonal antibodies products segment can be attributed to the fact that a large number of the approved precision therapies are monoclonal antibodies. This large share of this segment is also supported by the ongoing approvals for monoclonal antibody drugs for various cancers and other diseases highlighting a focus of pharmaceutical companies on the development of monoclonal antibodies as precision medicines. The oncology subsegment accounted for the largest share of the precision diagnostics market's indication segment in 2023 Based on indication, the precision diagnostics market is segmented into oncology, neurology, immunology, and other indications. The oncology segment accounted for the largest share of the precision diagnostics market by indication in 2023. The large share of this segment is attributed to the increase in cancer cases globally, supported by rising demand for diagnostic tests offering early and accurate cancer diagnosis. For this reason, life science companies are increasingly investing and collaborating to develop advanced oncology diagnostic tests. This dominance is expected to continue throughout the forecast period as major players are developing new technologies for better oncology diagnosis. Asia Pacific is registered as the fastest-growing region of the Precision diagnostics market in 2023. The Precision medicine market is divided into five regions, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America held the largest share of the precision diagnostics market, followed by Europe. Aisa Pacific registered the highest CAGR growth within the precision diagnostics market during the forecast period. The expansion of key diagnostic players in the region followed by favorable policies supporting the larger adoption of precision medicine is a supporting factor. Additionally, there is a greater awareness about personalized approach to treatments in these developed regions compared to the developing/ emerging economies. Key players in the Precision diagnostic market include F. Hoffman La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), and Guardant Health (US) among others and key players in precision medicine market include Merck Co, Inc. (US), Gilead Sciences (US), AstraZeneca (UK), Novartis AG (Switzerland), among others. Don't miss out on business opportunities in Precision Diagnostics & Medicine Market. Speak to our analyst and gain crucial industry insights that will help your business grow.
New Indian Express
10-07-2025
- Health
- New Indian Express
Switzerland approves first malaria drug for infants
CHENNAI: Swiss-pharma major Novartis AG said early this week that its pediatric malaria treatment, Coartem Baby, received regulatory approval from Swissmedic, Switzerland's national medicines regulatory authority. This marks a milestone in global health, as this Novartis drug is the world's first malaria treatment specifically developed for newborns and infants weighing between 2 and 5 kilograms. Coartem Baby is a reformulation of the existing Coartem (artemether-lumefantrine) combination therapy. The new formulation was developed through a collaboration between Novartis and the Medicines for Malaria Venture (MMV), with support from the PAMAfrica consortium. The clinical development program was co-funded by the European & Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency. The approval was based on positive data from the Phase II/III CALINA study, which demonstrated that Coartem Baby has a pharmacokinetic profile suitable for infants under 5 kilograms and exhibits good efficacy and safety. Global Health Impact Malaria remains one of the world's deadliest diseases, particularly among children under five years old in Africa. In 2023, there were an estimated 36 million pregnancies in 33 African countries where malaria is widespread, with about one in three mothers infected with malaria during pregnancy, raising the risk of transmission to their newborns.
Bloomberg
03-07-2025
- Health
- Bloomberg
Novartis Blockbuster Antibody Drug Fails in Late-Stage Trial
Novartis AG 's drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a blow to the Swiss company's efforts to find new uses for the blockbuster medicine. The therapy, already one of Novartis's top sellers, did not demonstrate statistically significant improvement in adult patients suffering from giant cell arteritis, an ailment that can cause loss of vision and life-threatening aneurysms, according to a statement Thursday. The drug was compared with placebo, with all trial participants also getting a steroid.
